UNSPSC 51332522: Melperone hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C16H22FNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88G640374K, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-, hydrochloride but more generally known as melperone hydrochloride, which bears US NIH Compound Identifier 15386. European Medicines Agency schedules Melperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14503MIG.

Most nations, for tariff and trade purposes, schedule melperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, MELPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCN(CC1)CCCC(=O)C2CCC(CC2)F.CL.

UNSPSC 51332522 Melperone hydrochloride is a Commodity code that nominally identifies a single pharmaceutical product, but recent state and local opportunities show little activity directly tied to this specific chemical compound. The three most recent solicitations tagged under this code diverge substantially from melperone itself: Seminole County, Florida is procuring naloxone and drug deactivation systems; Texas HHS is exploring direct-to-manufacturer prescription programs broadly; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing statewide contracts for generic multi-source pharmaceuticals and OTC products generally. The mismatch between the code's nominal scope and the actual recent opportunities suggests either miscoding in state and local procurement systems or that melperone hydrochloride procurement activity is minimal or absent in the recent record. Issuing bodies using this code span county health departments (Seminole County), state HHS agencies (Texas), and multistate cooperative purchasing consortia (MMCAP administering on behalf of Minnesota and participating jurisdictions including Oregon).

Recent activity concentrates in the South and upper Midwest. Seminole County's IFB60459723LAS (IFB, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. Texas HHS issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, a preliminary market-intelligence exercise preceding formal competitive solicitation. MMCAP's S1070000015802 (RFP, due March 26, 2026) targets generic pharmaceuticals and OTC products through three authorized wholesalers with awarded vendors effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. No recent solicitation explicitly names melperone hydrochloride as a line item, and the code itself shows limited direct procurement signaling.